The AAR2 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Huh-7 hepatocellular carcinoma cell line. This product comprises a heterogeneous pool of cells carrying diverse loss-of-function mutations in the AAR2 gene, generated through CRISPR/Cas9-mediated gene disruption. The polyclonal format captures population-level variability in AAR2 deficiency, providing a robust model for studying gene function without the bias of single-cell clonal selection. This knockout pool is ideally suited for investigating AAR2-dependent cellular processes in a liver cancer context.
The parental Huh-7 cell line originates from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male and is widely utilized in hepatitis C virus (HCV) research and hepatic metabolism studies. Huh-7 cells maintain epithelial morphology and key hepatocyte features, making them a physiologically relevant model for liver tumor biology. When combined with AAR2 knockout, these cells offer a genetically tractable system to explore splicing-related mechanisms underlying hepatocellular carcinoma progression.
AAR2 is a co-chaperone critical for the assembly of the U5 small nuclear ribonucleoprotein (snRNP), a central component of the spliceosome. It chaperones the stable integration of PRPF8 into the U5 snRNP, an essential step for pre-mRNA splicing. AAR2 directly interacts with PRPF8, SNRNP200, and EFTUD2, and its expression is regulated by general transcription factors. Disruption of AAR2 impairs U5 snRNP biogenesis, causing widespread pre-mRNA splicing defects that alter alternative splicing of numerous downstream targets, including cancer-related genes. This places AAR2 at a pivotal regulatory node connecting transcription to post-transcriptional RNA processing.
In the hepatocellular carcinoma background of Huh-7 cells, AAR2 knockout disrupts spliceosome integrity, providing a powerful model to probe how splicing dysregulation contributes to liver tumorigenesis. The resulting global changes in alternative splicing can impact cell proliferation, apoptosis, and other cancer hallmarks, mirroring aspects of spliceosomopathies. This knockout pool enables the study of liver cancer cell dependency on efficient splicing machinery and supports the identification of therapeutic vulnerabilities associated with splicing factor loss in HCC.
This polyclonal knockout pool accommodates diverse research applications. Investigators can exploit RNA sequencing or RT-qPCR to profile global splicing alterations and quantify isoform-specific transcripts. Western blotting and co-immunoprecipitation assays permit assessment of U5 snRNP component abundance and complex integrity, while cell viability and proliferation assays reveal functional consequences of AAR2 loss. Immunofluorescence can monitor subcellular localization shifts of spliceosome factors. The model is also suitable for functional genomics screens, high-throughput identification of splicing-modulating compounds, and mechanistic dissection of U5 snRNP assembly. For additional technical information or custom solutions, please contact Ascent Research.
